Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer

Pharmaceuticals

Adam C. Reese²  Jill Hardin³  Iona Cheng⁴  Graham Casey¹ 

[1] Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA;Department of Urology, University of California at San Francisco, 1450 3^rd Street, San Francisco, CA 94158, USA; E-Mail:;Epidemiology and Biostatistics and Institute for Human Genetics, University of California at San Francisco, 1450 3^rd Street, San Francisco, CA 94158, USA; E-Mail:;Epidemiology Program, Cancer Research Center of Hawai`i, University of Hawai`i, Honolulu, HI 96813, USA

关键词: prostatic neoplasms;    non-steroidal anti-inflammatory agents;    aspirin;    genetic variation;    single nucleotide polymorphism;   

DOI  :  10.3390/ph3103127

来源: mdpi

【 摘 要 】

Increasing evidence suggests that prostatic inflammation plays a key role in the development of prostate cancer. It remains controversial whether non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of prostate cancer. Here, we investigate how a previously reported inverse association between NSAID use and the risk of aggressive prostate cancer is modulated by variants in several inflammatory genes. We found that NSAIDs may have differential effects on prostate cancer development, depending on one’s genetic makeup. Further study of these inflammatory pathways may clarify the mechanisms through which NSAIDs impact prostate cancer risk.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.